91AV

Introduction

Day One

• Regulatory Updates
• Analytics & quality control
• Case studies for successful commercialization
• The latest tools and technologies for quality control, off-target activity assessment and characterization of cell therapies
• Extended Characterisation Of rAAV Vectors By Mass Spectrometry

• Scalable platforms for viral vector production
• Viral and non-viral vector engineering
• Optimized cell line generation for manufacturing of biologics
• Cell Culture Processing
• 3D Media and Cell Culture
• Addressing Bioprocessing Strategies Automation & digitalization
• High throughput technologies in bioprocessing

Day Two

• Scalable platforms for viral vector production 
• Cryopreservation  

• End to End Supply chain 
• Cold Chain Strategies 
• cGMP Manufacturing 
• Scale-up of cell & gene therapy manufacturing through automation and digitalization 
• Single-use technologies 

Useful links

Speakers

• Shilpi Rajoria Bristol Myers Squibb, United States
• Kenneth Green Vertex Pharmaceuticals, United States
• Morgan O’Brien The Janssen Pharmaceutical Companies of Johnson & Johnson, Ireland
• Seshu Tummala Mana Therapeutics, United States
• Sarah Thomas Regenxbio, United States

---

Venue

Croke Park

Croke Park, Jones Road, Dublin, D03 P6K7, Ireland

Useful links

Committee

• Oxford Global United Kingdom

---

Organised by

Oxford Global

Contact information

Harry Liddiard
Oxford Global
+441865248455
Contact us by email

---